Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 10/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21964567 | 0.85 | POLB (0.38) | SMN1; SMN2L3MBTL1MEN1KMT2A | |
| SCHEMBL21961322 | 0.82 | MAP3K14 (0.42) | MAP3K14TLR9TLR8TLR7MEN1 | |
| SCHEMBL21960916 | 0.80 | ACHE (0.39) | SMN1; SMN2 | |
| SCHEMBL21961433 | 0.80 | MAP3K14 (0.36) | MAP3K14MEN1KMT2ADRD2 | |
| SCHEMBL21961429 | 0.79 | MAP3K14 (0.37) | MAP3K14TLR9TLR8TLR7 | |
| SCHEMBL21960896 | 0.78 | PIK3CD (0.39) | MAP3K14MEN1KMT2A | |
| SCHEMBL21960895 | 0.75 | MAPT (0.42) | — | |
| SCHEMBL21960380 | 0.75 | BRD4 (0.36) | SMN1; SMN2 | |
| SCHEMBL21960387 | 0.75 | BRD4 (0.37) | MAP3K14 | |
| SCHEMBL21960386 | 0.73 | MAP3K14 (0.37) | MAP3K14SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-05 | — | — | US | disclosed |
| EP-3478675-B1 | HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136311-B2 | Heteroaromatic derivatives as NIK inhibitors | NFKBIA, IKBKG, IKBKE | MAP3K14 4/4885TLR9 1157/4885TLR8 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.